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Time for a Paradigm Shift?*
Robert J. Applegate, MD
Winston-Salem, North Carolina
In the past 2 decades there has been tremendous evolution of
both the effectiveness and safety of percutaneous coronary
intervention (PCI). As coronary ischemic events have
decreased dramatically in frequency during and after PCI,
efforts to improve the safety of PCI have shifted to addressing
other complications, especially bleeding, occurring in the
periprocedural period. A growing body of literature has
shown that periprocedural bleeding is an independent
predictor of adverse events including death following PCI
(1). The term “bleeding avoidance strategies” has emerged
reﬂecting that multiple factors have been associated with an
increase in bleeding, and may have additive effects on this
outcome (2). Although multiple factors contribute to
bleeding after PCI, the access site (i.e., femoral or radial
artery) has recently come under intense scrutiny as a source of
potential bleeding, and by extension, a potential modiﬁable
factor in an effort to reduce bleeding complications.See pages 954 and 964The safety and efﬁcacy of cardiac catheterization (CATH)
and PCI performed via the radial (RA) or femoral access
(FA) in a wide variety of patients and circumstances has
been assessed in a number of small randomized trials and
multiple registries. In a recent meta-analysis of PCI studies
performed from both RA and FA incorporating many of
these studies, RA was found to have better outcomes
compared to FA for all metrics evaluated including access*Editorials published in the Journal of the American College of Cardiology reﬂect the
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RIVAL (RadIal Vs. femorAL) trial evaluated 7,021 patients
with an acute coronary syndrome randomized to undergo
PCI from either RA or FA (4). A signiﬁcant reduction in
the rates of major vascular access complications from 3.7%
to 1.4% with the use of RA compared with FA was observed
but no substantial differences in overall rates of bleeding or
in mortality were found. Based on the results of these
studies, and educational initiatives highlighting the relative
safety of the radial approach, there has been an upsurge in
the utilization of RA for both CATH and PCI (5).
As interest in utilization of RA for elective PCI has grown,
there has also been an increasing interest in the use of RA for
primary percutaneous coronary intervention (PPCI) for ST-
segment elevation myocardial infarction (STEMI).
Although there was not a signiﬁcant reduction in the primary
endpoint in the overall RIVAL cohort, in the subgroup of
patients treated with PPCI for STEMI (approximately one-
third of the overall cohort), there was a signiﬁcant reduction
in the primary endpoint with RA compared with FA,
including a decrease in mortality. In the RIFLE-STEACS
(Radial Versus Femoral Randomized Investigation in ST-
Elevation Acute Coronary Syndrome) trial comparing
outcomes in STEMI patients randomized to either RA or
FA, similar observations were made (6). Interestingly, in the
subgroup of STEMI patients in the RIVAL trial as well as in
the MORTAL (Mortality beneﬁt Of Reduced Transfusion
after percutaneous intervention via Arm or Leg) trial (7) and
the RIFLE-STEAC trial, there was a signiﬁcant reduction
in mortality with the radial approach as opposed to the
femoral approach. Although these studies were not designed
to address mortality as the primary endpoint, nor the
potential mechanism of lower mortality with RA, it is
presumed that the decrease in mortality observed with RA
was related to a decrease in access site and bleeding
complications associated with the radial approach.
In this issue of the Journal, 2 studies further address the
issue of RA versus FA for PPCI for STEMI. First, Bernat
et al. (8) present the results of the STEMI-RADIAL trial
(ST Elevation Myocardial Infarction Treated by RADIAL
or Femoral Approach), a multicenter (n ¼ 4) randomized
trial of PPCI for STEMI. The study was designed to
evaluate only PPCI for STEMI, and excluded patients
with thrombolysis or cardiogenic shock who were included
in the STEMI subgroup of RIVAL and in RIFLE-
STEACS. The primary endpoint was the cumulative inci-
dence of major bleeding and access site complications at 30
days, with a second primary endpoint of net adverse clinical
events (NACE) deﬁned as a composite of death, myocardial
infarction, stroke, and major bleeding/vascular complica-
tions. The primary endpoint occurred in 1.4% of RA
(n ¼ 348) and 7.2% of FA (n ¼ 359; p ¼ 0.001). NACE
occurred in 4.6% of RA and 11.0% of FA (p ¼ 0.028),
although mortality rates were similar (2.3% vs. 3.6%,
respectively; p ¼ 0.31). The authors concluded that “in
patients with STEMI undergoing PPCI by operators
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associated with signiﬁcantly lower incidence of major
bleeding and access site complications and superior net
clinical beneﬁt. These ﬁndings support the use of the radial
approach in PPCI as ﬁrst choice after proper training.”
In the second study, Jolly et al. (9) evaluated the role of
center and operator RA and FA volume on procedural
metrics and clinical outcomes in a substudy of the RIVAL
trial. The authors found a strong interaction between overall
and RA center volumes, and clinical outcomes, but not FA
center volumes. Overall PCI and RA operator volumes
were also associated with lower rates of the primary study
endpoint. The rationale offered by the authors of this
apparent dichotomy was that femoral volumes were much
higher than reported in previous studies such that all centers
were equally expert in femoral, but not radial, PCI. As the
impetus to increase utilization of RA increases, the issue of
RA experience will become important in the overall
discussion of the relative merits of RA versus FA for PCI.
What constitutes proﬁciency sufﬁcient to be characterized
as “radial expert” remains unclear. Experience as little as
50 cases has been suggested as the minimum to develop
proﬁciency (10), but multiple studies indicate that continued
proﬁciency continues to be accrued with higher RA volumes,
particularly at high- volume radial centers.
The results of the RADIAL-STEMI trial (8) and the
RIVAL substudy (9) complement the observations made
from the STEMI subgroup of RIVAL (4) and RIFLE-
STEACS (6) trials. Each of the studies used slightly
different endpoints so it is difﬁcult to precisely compare
results, but some reasonable generalizations can be made
about these studies. The reduction in access site complica-
tions with RA compared with FA was directionally similar
in all studies. Interestingly, overall bleeding was not reduced
in these studies, largely because non–access site bleeding was
not different for the RA and FA groups, and accounted for
at least 50% of overall major bleeding. Mortality was lower
in the RA versus FA groups in the STEMI subgroup of
RIVAL and in RIFLE-STEACS trials, but not in the
RADIAL-STEMI trial. As the authors of the RADIAL-
STEMI trial concluded, the results from these studies
make a strong argument for considering a paradigm shift
to RA rather than FA for PPCI of STEMI.
The issue of a potential decrease in mortality with RA
versus FA in PPCI for STEMI is important as it would
provide a compelling argument to switch to a preferred RA
approach, rather than switching based on a reduction in
access site complications alone. In the August issue of JACC:
Cardiovascular Interventions, Karrowni et al. (11) presented
a meta-analysis of RA versus FA trials (n ¼ 12) of PPCI
for STEMI and found an odds ratio of 0.55 (95% conﬁ-
dence interval [CI]: 0.40 to 0.76; p < 0.001) for a decrea-
sed risk of death with RA versus FA. In an accompanying
editorial Mahmud and Patel cautioned against overinter-
pretation of these observations because of methodolo-
gic differences in the studies, and urged for an adequatelypowered clinical trial to provide a deﬁnitive answer to the
issue of a reduction in mortality with RA for PPCI for
STEMI (12). Nonetheless, in the absence of a deﬁnitive
answer to the question of a reduction in mortality with RA,
the existing data suggest that at worst RA is equivalent to
FA with regard to mortality, and may well be lower.
The RA approach was introduced several decades ago but
received little uptake because of issues including spasm,
variations in the pathway from the wrist to the ascending
aorta, limitations in catheter sizes, as well as less than
optimal equipment tailored speciﬁcally for the radial
approach (13). However, improvements in technology, and
in technique, have dramatically overcome many of these
limitations. Yet several concerns persist among interven-
tionalists, particularly with regard to PCI performed from
the RA, that continue to limit wider utilization of this
approach, including: concern that RA takes longer and is
associated with higher radiation exposure than FA cases; the
RA will make adherence to a 90-min door-to-balloon time
(DTB) metric problematic; and that it may limit interven-
tional options in complex cases.
The perception that RA has a “steep learning curve,” takes
longer to perform, and is associated with higher radiation
exposure have been addressed by multiple studies as well as
by a post hoc analysis of the RIVAL trial (14). In the
RIVAL trial, overall ﬂuoroscopy times were slightly longer
for radial than femorald9.3 min (95% CI: 5.8 to 15.0 min)
versus 8.0 min (95% CI: 4.5 to 13.0 min; p < 0.01)dbut
these differences were substantially mitigated by high-
volume operators and centers. Similarly, air kerma was
slightly higher for radial compared with femoral cases, but
the difference was seen almost exclusively among low-
volume centers. These data, as well as the data from Bernat
et al. (8) strongly support the concept that experience with
RA can eliminate differences in procedure time and radia-
tion exposure between these two approaches, while
preserving the safety beneﬁt of RA versus FA.
Despite a widely held perception in the United States
that radial PPCI for STEMI takes “a lot longer” and FA is
the preferred approach, the existing data suggest that the
increase in time associated with the radial approach is small
and does not preclude performing routine STEMI cases with
a DTB time under 90 min (15,16). In the RIFLE-STEACS
trial DTBs were 53 min (31 to 91 min) for radial and 60 min
(35 to 99 min) for femoral (p ¼ 0.175) (6). Thus, there was
a small nonsigniﬁcant increase in DTB with the radial
approach, but DTBs well under 90 min were still achieved
with the radial approach. In the RADIAL-STEMI trial,
DTBs were very low and similar in both RA and FA groups,
32  11 min and 31  11 min, respectively (p ¼ 0.31).
Crossover rates for RA, necessitating a femoral approach
anyway, are a particular concern in PPCI for STEMI.
However, the crossover rate for RA to FA in the RADIAL-
STEMI trial was only 3.7% and the analysis of DTB was
done on an intention- to- treat basis. Admittedly, the radial
operators in both studies were very experienced, but these
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cannot be performed in a timely fashion from the radial
approach with adequate training and experience. As noted in
their editorial, Mahmud and Patel caution that PPCI for
STEMI should only be attempted when substantial experi-
ence with RA in elective cases has been obtained (12).
There also has been concern among interventionalists
that the radial approach may limit their options in complex
cases, and that the urgent need for revascularization in
a STEMI case requires the most ﬂexible approach be taken
(i.e., FA). However, techniques have evolved that allow
complex PCI, for example use of a sheathless guide tech-
nique, and sequential two- stent strategies among others, as
well as treatment of graft patients via the left radial artery.
Finally, patients with shock complicating a STEMI are
problematic. If support devices are expected to be required,
a FA approach is needed for the support device, with PPCI
performed from RA or FA on the basis of the operators’
experience and comfort level. Ultimately, these technical
considerations do not appear to be issues among high-
volume RA operators at high- volume centers.
The studies reviewed above are helping shape the evidence
base surrounding the relative beneﬁts of RA versus FA for
PPCI for STEMI. What should we take away from
these studies? First, in experienced centers with experienced
operators, procedures performed from the radial artery can
be performed in the same length of time, using the same
amount of radiation and contrast, as the same procedures
performed from the femoral artery. Second, access site
complications are consistently lower with RA than FA, as
would be expected. Third, PPCI for STEMI can be per-
formed via RA with DTBs clinically equivalent to those
performed from FA after adequate experience and training.
Finally, mortality is the same or possibly lower with RA
versus FA for PPCI for STEMI. Based on these con-
siderations is it time for a paradigm shift to a preferred RA
approach for PPCI for STEMI? Based on these new studies
the answer appears to be yes. Moreover, this transition
from preferred FA to preferred RA for PPCI for STEMI
represents a natural evolution of strategies aimed at
improving safety of coronary interventions. To reap the full
beneﬁt of the radial approach, however, a concerted effort by
both interventional centers and operators to achieve proﬁ-
ciency in performing PCI from the radial artery will be
needed.
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